Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hedy L Kindler

Showing results (11-20 of 157) with videos related to

Pageof 16
Sort By:
Lung Cancer (Amsterdam, Netherlands)|April 16, 2004
Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807)Gregory A Otterson, James E Herndon, Dorothy Watson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2002
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancerRichard L Schilsky, Donna Bertucci, Nicholas J Vogelzang, et al.
Journal of Medical Imaging (Bellingham, Wash.)|December 13, 2024
Radiomics for differentiation of somatic <i>BAP1</i> mutation on CT scans of patients with pleural mesotheliomaMena Shenouda, Abbas Shaikh, Ilana Deutsch, et al.
Investigational New Drugs|May 4, 2004
9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortiumHedy L Kindler, Anjali Avadhani, Kurombi Wade-Oliver, et al.
Journal of Pain and Symptom Management|November 23, 2011
Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303)Dorothy Romanus, Hedy L Kindler, Laura Archer, et al.
The Annals of Thoracic Surgery|August 31, 2015
Extended Pleurectomy and Decortication for Malignant Pleural Mesothelioma Is an Effective and Safe Cytoreductive Surgery in the ElderlyTrevor Williams, Hadi Duraid, Sydeaka Watson, et al.
Academic Radiology|September 24, 2005
Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scansSamuel G Armato, Geoffrey R Oxnard, Masha Kocherginsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2004
Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumorsManisha H Shah, Donn Young, Hedy L Kindler, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|January 24, 2016
Specimen weight and volume: important predictors of survival in malignant pleural mesotheliomaDiana Y Kircheva, Aliya N Husain, Sydeaka Watson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2012
Optimization of response classification criteria for patients with malignant pleural mesotheliomaZacariah E Labby, Samuel G Armato, Hedy L Kindler, et al.
Pageof 16

Showing results (11-20 of 157) with videos related to

Sort By:
Pageof 16
Lung Cancer (Amsterdam, Netherlands)|April 16, 2004
Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807)Gregory A Otterson, James E Herndon, Dorothy Watson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2002
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancerRichard L Schilsky, Donna Bertucci, Nicholas J Vogelzang, et al.
Journal of Medical Imaging (Bellingham, Wash.)|December 13, 2024
Radiomics for differentiation of somatic <i>BAP1</i> mutation on CT scans of patients with pleural mesotheliomaMena Shenouda, Abbas Shaikh, Ilana Deutsch, et al.
Investigational New Drugs|May 4, 2004
9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortiumHedy L Kindler, Anjali Avadhani, Kurombi Wade-Oliver, et al.
Journal of Pain and Symptom Management|November 23, 2011
Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303)Dorothy Romanus, Hedy L Kindler, Laura Archer, et al.
The Annals of Thoracic Surgery|August 31, 2015
Extended Pleurectomy and Decortication for Malignant Pleural Mesothelioma Is an Effective and Safe Cytoreductive Surgery in the ElderlyTrevor Williams, Hadi Duraid, Sydeaka Watson, et al.
Academic Radiology|September 24, 2005
Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scansSamuel G Armato, Geoffrey R Oxnard, Masha Kocherginsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2004
Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumorsManisha H Shah, Donn Young, Hedy L Kindler, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|January 24, 2016
Specimen weight and volume: important predictors of survival in malignant pleural mesotheliomaDiana Y Kircheva, Aliya N Husain, Sydeaka Watson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2012
Optimization of response classification criteria for patients with malignant pleural mesotheliomaZacariah E Labby, Samuel G Armato, Hedy L Kindler, et al.
Pageof 16